New hope for Platinum-Resistant ovarian cancer: BL-B01D1 enters phase 3 trial
NCT ID NCT06994195
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 3 trial tests a new drug called BL-B01D1 against standard chemotherapy in 384 women with ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based treatment. The goal is to see if BL-B01D1 can slow disease progression and improve survival. Participants receive either BL-B01D1 or one of three standard chemotherapies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BL-B01D1 (a drug given by IV every 3 weeks)
What this could lead to
If it works, this could offer a new treatment option for women with ovarian cancer that no longer responds to platinum-based chemotherapy.
What could go wrong
This is an early Phase 3 trial, so results are not guaranteed. The drug may not work better than current chemotherapies and could have side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY PERITONEAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, China
Contact